Boston Scientific Corporation
BSX.F
Get informed when a big investor buys or sells
+ FollowMarket Cap$56.58B
Close$
$43.80
13.8% upside
Current Fair Value
13.8% upsideUndervalued by 13.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $56.58 Billion |
|---|---|
| Enterprise Value | $69.06 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.96 |
| Beta | 0.57 |
| Outstanding Shares | 1,470,200,000 |
Return
| Return on Equity | 14.71% |
|---|---|
| Return on Assets | 8.11% |
| Return on Invested Capital | 10.85% |
Valuation & Multiples
| P/E Ratio | 17.23 |
|---|---|
| PEG | 124.84 |
| Price to Sales | 2.75 |
| Price to Book Ratio | 2.26 |
| Enterprise Value to Revenue | 3.29 |
| Enterprise Value to EBIT | 16.41 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.52 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$0.73
Average shareholder expectationRevenue Estimate
$4.71 B
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$0.66
Average shareholder expectationRevenue Estimate
$4.52 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Boston Scientific Corporation
45,000 employees
CEO: Michael F. Mahoney Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The com...